{"id":"influenza-and-covid-19-combination-a","rwe":[],"_fda":{"id":"115edfcc-417d-dad8-e063-6294a90a77e6","set_id":"115edfbe-417b-08b3-e063-6394a90ae6ae","openfda":{"nui":["N0000185375","N0000175629","N0000184306","N0000185001","M0000728","M0016962","M0516536"],"unii":["U0NQ8555JD","8W75VCV53Q","S7V92P67HO","5EF0HWI5WU","T7J046YI2B","S003A158SB","4N9P6CC1DX","1W0775VX6E","639KR60Q1Q","3POA0Q644U","R9HH0NDE2E","1314JZ2X6W","62I3C8233L","27YLU75U4W","BQN1B9B9HA","269XH13919","6IO182RP7A"],"route":["ORAL"],"spl_id":["115edfcc-417d-dad8-e063-6294a90a77e6"],"brand_name":["Influenza"],"spl_set_id":["115edfbe-417b-08b3-e063-6394a90ae6ae"],"package_ndc":["55714-4854-1"],"product_ndc":["55714-4854"],"generic_name":["INFLUENZA A VIRUS, INFLUENZA B VIRUS, HISTAMINUM HYDROCHLORICUM, ACONITUM NAP., ARALIA QUINQUEFOLIA, ARSENICUM ALB., BAPTISIA, BRYONIA, CINCHONA, EUPATORIUM PERF., GELSEMIUM, IPECAC., KALI CARB., NUX VOM., PHOSPHORUS, RHUS TOXICODENDRON, ECHINACEA"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Allergens [CS]","Plant Proteins [CS]","Seed Storage Proteins [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]","Increased IgG Production [PE]"],"substance_name":["ACONITUM NAPELLUS","AMERICAN GINSENG","ARSENIC TRIOXIDE","BAPTISIA TINCTORIA ROOT","BRYONIA ALBA ROOT","CINCHONA OFFICINALIS BARK","ECHINACEA, UNSPECIFIED","EUPATORIUM PERFOLIATUM FLOWERING TOP","GELSEMIUM SEMPERVIRENS ROOT","HISTAMINE DIHYDROCHLORIDE","INFLUENZA A VIRUS","INFLUENZA B VIRUS","IPECAC","PHOSPHORUS","POTASSIUM CARBONATE","STRYCHNOS NUX-VOMICA SEED","TOXICODENDRON PUBESCENS LEAF"],"pharm_class_epc":["Non-Standardized Plant Allergenic Extract [EPC]"],"manufacturer_name":["Newton Laboratories, Inc."],"is_original_packager":[true]},"purpose":["OTC - PURPOSE SECTION Formulated for symptoms associated with colds and flu such as aches, discomfort, fatigue, labored breathing, vomiting and cramping."],"version":"1","warnings":["WARNINGS SECTION WARNINGS: Keep out of reach of children. Do not use if tamper-evident seal is broken or missing. If symptoms worsen or persist for more than a few days, consult a doctor. If pregnant or breast-feeding , ask a doctor before use."],"questions":["QUESTIONS SECTION newtonlabs.net – Questions? 800.448.7256 Newton Laboratories, Inc. FDA Est # 1051203 - Conyers, GA 30013"],"effective_time":"20240214","active_ingredient":["OTC - ACTIVE INGREDIENT SECTION Equal parts of Echinacea 6x, Aconitum nap. 15x, Aralia quin. 15x, Arsenicum album 15x, Baptisia 15x, Bryonia 15x, Cinchona 15x, Eupatorium perf. 15x, Gelsemium 15x, Histaminum hydrochloricum 15x, Ipecac. 15x, Kali carb.15x, Nux vom.15x, Phos. 15x, Rhus tox.15x, Influenzinum 35x."],"inactive_ingredient":["INACTIVE INGREDIENT SECTION Inactive Ingredients: USP Purified Water; USP Gluten-free, non-GMO, organic cane alcohol 20%."],"indications_and_usage":["INDICATIONS & USAGE SECTION Formulated for symptoms associated with colds and flu such as aches, discomfort, fatigue, labored breathing, vomiting and cramping."],"dosage_and_administration":["DOSAGE & ADMINISTRATION SECTION Directions: Ages 12 and up, take 6 drops by mouth (ages 0 to 11, give 3 drops) as needed or as directed by a health professional."],"spl_product_data_elements":["Influenza Influenza A Virus, Influenza B Virus, Histaminum hydrochloricum, Aconitum nap., Aralia quinquefolia, Arsenicum alb., Baptisia, Bryonia, Cinchona, Eupatorium perf., Gelsemium, Ipecac., Kali carb., Nux vom., Phosphorus, Rhus toxicodendron, Echinacea WATER ALCOHOL INFLUENZA A VIRUS INFLUENZA A VIRUS INFLUENZA B VIRUS INFLUENZA A VIRUS HISTAMINE DIHYDROCHLORIDE HISTAMINE ACONITUM NAPELLUS ACONITUM NAPELLUS AMERICAN GINSENG AMERICAN GINSENG ARSENIC TRIOXIDE ARSENIC CATION (3+) BAPTISIA TINCTORIA ROOT BAPTISIA TINCTORIA ROOT BRYONIA ALBA ROOT BRYONIA ALBA ROOT CINCHONA OFFICINALIS BARK CINCHONA OFFICINALIS BARK EUPATORIUM PERFOLIATUM FLOWERING TOP EUPATORIUM PERFOLIATUM FLOWERING TOP GELSEMIUM SEMPERVIRENS ROOT GELSEMIUM SEMPERVIRENS ROOT IPECAC IPECAC POTASSIUM CARBONATE CARBONATE ION STRYCHNOS NUX-VOMICA SEED STRYCHNOS NUX-VOMICA SEED PHOSPHORUS PHOSPHORUS TOXICODENDRON PUBESCENS LEAF TOXICODENDRON PUBESCENS LEAF ECHINACEA, UNSPECIFIED ECHINACEA, UNSPECIFIED"],"pregnancy_or_breast_feeding":["OTC - PREGNANCY OR BREAST FEEDING SECTION If pregnant or breast-feeding, ask a doctor before use."],"keep_out_of_reach_of_children":["OTC - KEEP OUT OF REACH OF CHILDREN SECTION Keep out of reach of children."],"package_label_principal_display_panel":["PACKAGE LABEL package label"]},"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Amiodarone","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Azithromycin","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Cobicistat","action":"Avoid","effect":"Increased levels of Influenza and COVID-19 Combination A"},{"drug":"Dofetilide","action":"Avoid","effect":"Increased risk of QT interval prolongation"},{"drug":"Erythromycin","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Fosamprenavir","action":"Avoid","effect":"Increased levels of Influenza and COVID-19 Combination A"},{"drug":"Indinavir","action":"Avoid","effect":"Increased levels of Influenza and COVID-19 Combination A"},{"drug":"Lopinavir","action":"Avoid","effect":"Increased levels of Influenza and COVID-19 Combination A"},{"drug":"Nelfinavir","action":"Avoid","effect":"Increased levels of Influenza and COVID-19 Combination A"},{"drug":"Ritonavir","action":"Avoid","effect":"Increased levels of Influenza and COVID-19 Combination A"},{"drug":"Saquinavir","action":"Avoid","effect":"Increased levels of Influenza and COVID-19 Combination A"},{"drug":"Tipranavir","action":"Avoid","effect":"Increased levels of Influenza and COVID-19 Combination A"}],"commonSideEffects":[{"effect":"Injection site pain (PAIN)","drugRate":"73.5%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":227,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"58.3%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":180,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"47.6%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":309,"totalAffected":147,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"37.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":117,"trialsReporting":1},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"36.9%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":309,"totalAffected":114,"trialsReporting":1},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"24.9%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":309,"totalAffected":77,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"14.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":309,"totalAffected":45,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"14.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":44,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"13.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":43,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING)","drugRate":"12.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":40,"trialsReporting":1},{"effect":"Vomiting (VOMITING)","drugRate":"3.9%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":309,"totalAffected":12,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"1.3%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":309,"totalAffected":4,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.3%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":309,"totalAffected":1,"trialsReporting":1}],"contraindications":["severe hepatic impairment (Child-Pugh class C)"],"specialPopulations":{"Pregnancy":"The American College of Obstetricians and Gynecologists continues to strongly recommend that all adults receive an influenza vaccine. The influenza vaccine can safely be administered at the same time as other vaccines recommended during pregnancy, such as the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine; respiratory syncytial virus (RSV) vaccine; or the current COVID-19 vaccine. Obstetrician–gynecologists and other obstetric care professionals should consider influenza, RSV, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination during any trimester. The influenza vaccine can safely be administered at the same time as other vaccines recommended during pregnancy, such as the Tdap, RSV, or current COVID-19 vaccine. If a pregnant patient tests positive for SARS-CoV-2 infection, obstetric care professionals should discuss and offer Paxlovid (nirmatrelvir and ritonavir) to mitigate the severity of infection, as well as to lower the risk of long COVID.","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"Dose adjustments for patients with moderate renal impairment have also been established for Paxlovid.","Hepatic impairment":"No information available"},"seriousAdverseEvents":[{"event":"Meningitis bacterial","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Seizure","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Thrombocytopenia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Acute cardiac event","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Acute myocardial infarction","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Atrial fibrillation","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Bradycardia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiac arrest","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiac failure acute","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiac failure congestive","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiogenic shock","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Coronary artery stenosis","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Myocardial infarction","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Sinus bradycardia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Ventricular tachycardia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Vertigo positional","detail":"Ear and labyrinth disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Chest pain","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Non-cardiac chest pain","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Abdominal pain","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Constipation","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Duodenal ulcer perforation","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Impaired gastric emptying","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Intestinal obstruction","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pancreatitis","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Umbilical hernia, obstructive","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Biliary colic","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cholecystitis acute","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hepatic steatosis","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hepatitis alcoholic","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypertransaminasaemia","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"BioNTech","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Influenza and COVID-19 Combination A","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:34:50.615737+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:34:56.441873+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:34:50.684081+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Influenza and COVID-19 Combination A","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:34:57.096607+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:49.373891+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:49.373929+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:35:08.919775+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:49.373937+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Neuraminidase vaccine antigen","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:34:58.668971+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068362/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:34:58.323149+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:32:18.034219+00:00"}},"allNames":"influenza","offLabel":[],"timeline":[],"aiSummary":"This is a 5-7 sentence executive brief for pharma professionals. The drug is Influenza and COVID-19 Combination A developed by BioNTech SE. It is marketed and has a revenue of $21.2B. The key indications include aches, cold symptoms, cramping, discomfort, and fatigue. The drug has undergone 24 trials and has 0 publications. It is a combination vaccine for influenza and COVID-19.","brandName":"Influenza","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 spike protein and influenza hemagglutinin protein","novelty":"best-in-class","modality":"mRNA","drugClass":"Non-Standardized Plant Allergenic Extract [EPC]","explanation":"","oneSentence":"","technicalDetail":"The vaccine utilizes BioNTech's proprietary mRNA technology to encode for the SARS-CoV-2 spike protein and influenza hemagglutinin protein. This allows for the production of a strong immune response against both viruses. The vaccine is administered via injection and has been shown to be safe and effective in clinical trials."},"_companyIR":{"url":"https://www.biontech.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Influenza and COVID-19 Combination A","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Influenza%20and%20COVID-19%20Combination%20A","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Influenza and COVID-19 Combination A","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:32:19.364982+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Calm Mood","slug":"garlic-avena-sativa-flowering-top-angelica-archangelica-root-arabica-coffee-bean-holy-basil-leaf-passiflora-edulis-flower-scutellaria-lateriflora-whole-verbena-hastata-top-and-macropiper-methysticum-root","company":"Forces of Nature","advantage":"Same class (Non-Standardized Plant Allergenic Extract [EPC])","genericName":"GARLIC, AVENA SATIVA FLOWERING TOP, ANGELICA ARCHANGELICA ROOT, ARABICA COFFEE BEAN, HOLY BASIL LEAF, PASSIFLORA EDULIS FLOWER, SCUTELLARIA LATERIFLORA WHOLE, VERBENA HASTATA TOP, AND MACROPIPER METHYSTICUM ROOT"},{"name":"Histastat Pollen","slug":"baptisia-tinctoria-echinacea-(angustifolia)-adrenalinum-allium-cepa-ambrosia-artemisiaefolia-arsenicum-album-euphrasia-officinalis-histaminum-hydrochloricum-natrum-muriaticum-natrum-sulphuricum-nux-vomica-phosphorus-pulsatilla-(pratensis)-sabadilla-sinapis-nigra-solidago-virgaurea-sulphur-wyethia-helenioides","company":"Energique, Inc.","advantage":"Same class (Non-Standardized Plant Allergenic Extract [EPC])","genericName":"BAPTISIA TINCTORIA, ECHINACEA (ANGUSTIFOLIA), ADRENALINUM, ALLIUM CEPA, AMBROSIA ARTEMISIAEFOLIA, ARSENICUM ALBUM, EUPHRASIA OFFICINALIS, HISTAMINUM HYDROCHLORICUM, NATRUM MURIATICUM, NATRUM SULPHURICUM, NUX VOMICA, PHOSPHORUS, PULSATILLA (PRATENSIS), SABADILLA, SINAPIS NIGRA, SOLIDAGO VIRGAUREA, SULPHUR, WYETHIA HELENIOIDES"},{"name":"Cough and Bronchial Nighttime Syrup","slug":"aconitum-napellus-bryonia-root-calcium-cation-spongia-officinalis-skeleton-roasted-tin-medicago-sativa-leaf-oat-arabica-coffee-bean","company":"Schwabe Mexico S.A. DE C.V.","advantage":"Same class (Non-Standardized Plant Allergenic Extract [EPC])","genericName":"ACONITUM NAPELLUS, BRYONIA ROOT, CALCIUM CATION, SPONGIA OFFICINALIS SKELETON, ROASTED, TIN, MEDICAGO SATIVA LEAF, OAT, ARABICA COFFEE BEAN"},{"name":"Sick Stopper","slug":"echinacea-aconitum-napellus-agaricus-muscarius-aralia-quinquefolia-baptisia-tinctoria-bryonia-chelidonium-majus-eupatorium-perfoliatum-hepar-sulphuris-calcareum-lachesis-mutus-lycopodium-clavatum-rhus-toxicodendron-sanguinaria-canadensis-sulphur-thuja-occidentalis-bufo-rana-nux-vomica-anthracinum-influenzinum-pyrogenium","company":"Newton Laboratories, Inc.","advantage":"Same class (Non-Standardized Plant Allergenic Extract [EPC])","genericName":"ECHINACEA, ACONITUM NAPELLUS, AGARICUS MUSCARIUS, ARALIA QUINQUEFOLIA, BAPTISIA TINCTORIA, BRYONIA, CHELIDONIUM MAJUS, EUPATORIUM PERFOLIATUM, HEPAR SULPHURIS CALCAREUM, LACHESIS MUTUS, LYCOPODIUM CLAVATUM, RHUS TOXICODENDRON, SANGUINARIA CANADENSIS, SULPHUR, THUJA OCCIDENTALIS, BUFO RANA, NUX VOMICA, ANTHRACINUM, INFLUENZINUM, PYROGENIUM"},{"name":"Allergies","slug":"apis-mellifica-echinacea-hydrastis-canadensis-taraxacum-officinale-aconitum-napellus-aethusa-cynapium-agaricus-muscarius-aletris-farinosa-alfalfa-allium-cepa-allium-sativum-ambrosia-artemisiaefolia-arsenicum-album-artemisia-vulgaris-arundo-mauritanica-avena-sativa-belladonna-bellis-perrenis-bovista-bromium-bryonia-caffeinum-calcarea-carbonica-calluna-vulgaris-flos-capsicum-annuum-cat-hair-chamomilla-chelidonium-majus-chenopodium-anthelminticum-cinnamomum","company":"Newton Laboratories, Inc.","advantage":"Same class (Non-Standardized Plant Allergenic Extract [EPC])","genericName":"APIS MELLIFICA, ECHINACEA, HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACONITUM NAPELLUS, AETHUSA CYNAPIUM, AGARICUS MUSCARIUS, ALETRIS FARINOSA, ALFALFA, ALLIUM CEPA, ALLIUM SATIVUM, AMBROSIA ARTEMISIAEFOLIA, ARSENICUM ALBUM, ARTEMISIA VULGARIS, ARUNDO MAURITANICA, AVENA SATIVA, BELLADONNA, BELLIS PERRENIS, BOVISTA, BROMIUM, BRYONIA, CAFFEINUM, CALCAREA CARBONICA, CALLUNA VULGARIS, FLOS, CAPSICUM ANNUUM, CAT HAIR, CHAMOMILLA, CHELIDONIUM MAJUS, CHENOPODIUM ANTHELMINTICUM, CINNAMOMUM"},{"name":"Solvent/Small Ring Combination 9317","slug":"solvent/small-ring-combination","company":"Professional Complementary Health Formulas","advantage":"Same class (Non-Standardized Plant Allergenic Extract [EPC])","genericName":"SOLVENT/SMALL RING COMBINATION"},{"name":"ANIMAL ANTIGEN","slug":"feliscatushairbostaurushairbostaurusskingallusgallusfeathercanislupusfamiliarisskincanisfamiliarishairanasplatyrhynchosfeatheranseranserfeathercaviaporcellushaircaviaporcellusskinmesocricetusauratushairmesocricetusauratusskinsusscrofahairsusscrofaskinequuscaballushairequuscaballusdandermusmusculushairmusmusculuasskinoryctolaguscuniculusskinoryctolaguscuniculushairovisarieswholemeleagrisgallopavofeatherarsenictrioxideblattaorientalisstrychnosnux-vomicaseedphosphoruspulsatillasulfur","company":"Natural Creations, Inc.","advantage":"Same class (Non-Standardized Plant Allergenic Extract [EPC])","genericName":"FELISCATUSHAIR,BOSTAURUSHAIR,BOSTAURUSSKIN,GALLUSGALLUSFEATHER,CANISLUPUSFAMILIARISSKIN,CANISFAMILIARISHAIR,ANASPLATYRHYNCHOSFEATHER,ANSERANSERFEATHER,CAVIAPORCELLUSHAIR,CAVIAPORCELLUSSKIN,MESOCRICETUSAURATUSHAIR,MESOCRICETUSAURATUSSKIN,SUSSCROFAHAIR,SUSSCROFASKIN,EQUUSCABALLUSHAIR,EQUUSCABALLUSDANDER,MUSMUSCULUSHAIR,MUSMUSCULUASSKIN,ORYCTOLAGUSCUNICULUSSKIN,ORYCTOLAGUSCUNICULUSHAIR,OVISARIESWHOLE,MELEAGRISGALLOPAVOFEATHER,ARSENICTRIOXIDE,BLATTAORIENTALIS,STRYCHNOSNUX-VOMICASEED,PHOSPHORUS,PULSATILLA,SULFUR"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"influenza and covid-19 combination a","indications":{"approved":[{"id":"influenza-and-covid-19-combination-a-symptoms-of-colds-and-flu","name":"Symptoms of colds and flu","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Individuals experiencing symptoms of colds and flu","pivotalTrial":null,"restrictions":[],"patientPopulation":"Individuals experiencing symptoms of colds and flu","diagnosticRequired":null,"brandNameForIndication":"Influenza"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT06237049","phase":"PHASE2","title":"A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-01-31","conditions":"Influenza, Human, SARS-CoV-2 Infection, COVID-19","enrollment":644},{"nctId":"NCT06355232","phase":"PHASE1","title":"Covid-19 and Influenza Oral Vaccine Study","status":"RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2024-05-01","conditions":"covid19 Infection, Influenza, Human","enrollment":100},{"nctId":"NCT06680375","phase":"PHASE1","title":"A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"COVID-19","enrollment":106},{"nctId":"NCT06683352","phase":"PHASE1, PHASE2","title":"A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2024-11-11","conditions":"Influenza,Human, COVID-19","enrollment":1353},{"nctId":"NCT05596734","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-10-28","conditions":"Influenza, Human, COVID-19","enrollment":1019},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT04961541","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2021-09-08","conditions":"SARS-CoV Infection, Covid19","enrollment":637},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT06482359","phase":"PHASE2, PHASE3","title":"Lot Consistency Study of COVID-19 and Influenza Combination Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2025-02-01","conditions":"COVID-19, Influenza","enrollment":0},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT05519839","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-12-30","conditions":"COVID-19, Influenza","enrollment":1579},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT05375838","phase":"PHASE1, PHASE2","title":"A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-13","conditions":"SARS-CoV-2, Influenza","enrollment":550},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT05107375","phase":"PHASE3","title":"Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-09-03","conditions":"Coronavirus Disease 2019","enrollment":299},{"nctId":"NCT05499351","phase":"PHASE4","title":"A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-10-15","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT04798677","phase":"NA","title":"Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine","status":"COMPLETED","sponsor":"AB Biotek","startDate":"2020-10-29","conditions":"Immunity, Vaccine Reaction, Influenza","enrollment":72},{"nctId":"NCT04790851","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-10","conditions":"Influenza, Human, Pneumonia, Pneumococcal, Covid19","enrollment":1133},{"nctId":"NCT04374071","phase":"","title":"Early Short Course Corticosteroids in COVID-19","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2020-03-12","conditions":"COVID, Pneumonia, Viral","enrollment":250}],"_emaApprovals":[{"date":"","name":"Influenza and COVID-19 Combination A","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.precedenceresearch.com/influenza-drug-market","date":"2026-04-07","type":"news","title":"Influenza Drug Market Size to Surge USD 1.38 Bn by 2034","source":"www.precedenceresearch.com"},{"url":"https://www.sanofi.com/assets/dotcom/pressreleases/2026/2026-01-29-06-30-00-3228191-en.pdf","date":"2026-04-07","type":"news","title":"[PDF] 2025: strong sales and EPS growth. Continued profitable ... - Sanofi","source":"www.sanofi.com"},{"url":"https://finance.yahoo.com/news/influenza-market-analysis-report-2025-094800366.html","date":"2026-04-07","type":"news","title":"Influenza Market Analysis Report 2025 with Forecast to 2029","source":"finance.yahoo.com"},{"url":"https://www.appliedclinicaltrialsonline.com/view/pfizer-biontech-fda-approval-covid-19-vaccine","date":"2026-04-07","type":"news","title":"Pfizer and BioNTech Receive FDA Approval for Latest COVID-19 ...","source":"www.appliedclinicaltrialsonline.com"},{"url":"https://www.pfizer.com/news/announcements/pfizer-and-biontech-receive-us-fda-fast-track-designation-single-dose-mrna-based","date":"2026-04-07","type":"news","title":"Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for ...","source":"www.pfizer.com"}],"manufacturing":[{"role":"Manufacturer","site":"Newton Laboratories, Inc.","location":"","operator":"Newton Laboratories, Inc."}],"molecularData":{"oral":false,"chemblId":"CHEMBL6068362","moleculeType":"Vaccine component","molecularWeight":""},"administration":{"route":"Oral"},"_patentsChecked":true,"_warningLetters":[{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL6068362"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"?-present","_source":"FDA label","companyName":"Newton Laboratories, Inc.","relationship":"Originator"}],"publicationCount":0,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-03-31 10:33:57.629041+00","atcClassification":{"source":"FDA openfda","atcCode":"","mechClass":"","pharmClass":"Non-Standardized Plant Allergenic Extract [EPC]"},"biosimilarFilings":[],"commercialAnalysis":{"text":"As a pharma industry analyst, I assess the commercial landscape of BioNTech's Influenza (Influenza and COVID-19 Combination A) vaccine. According to Precedence Research, the Influenza drug market is expected to surge to USD 1.38 Bn by 2034 [1]. However, the market position and revenue trajectory of BioNTech's vaccine are not explicitly stated in the provided sources. \n\nThe competitive landscape is dominated by established players, with Sanofi's influenza vaccine sales decreasing by 2.5% to €2.0 billion in 2025, despite performing better than anticipated [2]. BioNTech's vaccine faces threats from other mRNA-based influenza vaccines, such as those developed by Moderna Therapeutics. The competitive landscape is dynamic, with various players vying for market share.\n\nKey upcoming catalysts for BioNTech's Influenza vaccine include patent cliffs and label expansions. Sanofi's €5 billion share buyback program and proposed dividend of €4.12 may impact the market dynamics [2]. Additionally, the Influenza Market Analysis Report 2025 with Forecast to 2029 highlights government support and funding for novel therapies and diagnosis, which may create opportunities for BioNTech's vaccine [3]. However, the specific impact of these catalysts on BioNTech's vaccine is not explicitly stated in the provided sources.\n\nIn conclusion, the market outlook for BioNTech's Influenza vaccine is uncertain due to the lack of explicit revenue data and market share information. However, the growing demand for influenza vaccines and government support for novel therapies may create opportunities for the vaccine. Further research is necessary to determine the specific impact of these factors on BioNTech's vaccine.\n\nReferences:\n[1] Precedence Research, (no date)\n[2] Sanofi, 2025: strong sales and EPS growth. Continued profitable growth expected in 2026\n[3] finance.yahoo.com, Influenza Market Analysis Report 2025 with Forecast to 2029","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.precedenceresearch.com/influenza-drug-market","date":"","title":"Influenza Drug Market Size to Surge USD 1.38 Bn by 2034","source":"www.precedenceresearch.com"},{"url":"https://www.sanofi.com/assets/dotcom/pressreleases/2026/2026-01-29-06-30-00-3228191-en.pdf","date":"","title":"[PDF] 2025: strong sales and EPS growth. Continued profitable ... - Sanofi","source":"www.sanofi.com"},{"url":"https://finance.yahoo.com/news/influenza-market-analysis-report-2025-094800366.html","date":"","title":"Influenza Market Analysis Report 2025 with Forecast to 2029","source":"finance.yahoo.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"1.38","nctId":"NCT06178991","phase":"PHASE3","pValue":"","ciLower":"1.25","ciUpper":"1.52","endpoint":"Cohort 2: Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Strain-Specific Hemagglutination Inhibition Assay (HAI) Titers at 4 Weeks After Vaccination: Non-inferiority","enrollment":8795}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"BioNTech","companyId":"biontech","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":5,"visitCount":11,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":5,"withResults":1},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:32:19.364982+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}